Please assess the completion status of the following clinical trial:

Trial Title: Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The patient must have given his/her informed and signed consent~* The patient must be insured or beneficiary of a health insurance plan~* The patient is not taking systemic treatment~* The patient has not been treated with topical steroids for more than 15 days.~For the bullous pemphigoid group:~* clinical signs: erythematous-based lesions, especially on flexion areas of the arms and legs, not afflicting mucous membranes, and without atrophic scaring~* histology: without epidermal acantholysis~For the pemphigus group:~* patient with pemphigus~For the lupus group:~* systemic lupus patients: presence of the 4 diagnostic criteria for systemic lupus erythematosus as defined by the American College of Rheumatology (amended 1997)~* or characteristics of subacute cutaneous lupus: clinical, histological and immunological (anti-SSa)~* or clinical and histological characteristics of chronic lupus~For the control group:~* hospitalized patients with no history of auto-immune, inflammatory or evolving neoplastic disease~Exclusion Criteria:~* The patient is participating in another study~* The patient is in an exclusion period determined by a previous study~* The patient is under judicial protection, under tutorship or curatorship~* The patient refuses to sign the consent~* It is impossible to correctly inform the patient~* The patient is pregnant, parturient, or breastfeeding~For patients with bullous pemphigoid, pemphigus or lupus:~* The patient is taking systemic treatment~* The patient has been taking topical steroids for more than 15 days.~For the controls:~* autoimmune disease~* inflammatory disease~* evolving neoplastic disease~* surgery during the last 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Bullous pemphigoid (Type: None): Patients in this cohort are newly diagnosed (or have not started treatment) with bullous pemphigoid
- Other bullous-like auto-immune (Type: None): Patients in this cohort are newly diagnosed (or have not started treatment) with pemphigus (15 patients) or cutaneous lupus (15 patients)
- Control group (Type: None): Patients in this cohort are hospitalized at the Nîmes University Hospital, and have no history of autoimmune, inflammatory or neoplastic disease. Patients are matched for age and sex with patients in the bullous pemphigoid cohort.

Based on this trial design, predict the completion outcome and termination type (if applicable).